1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Hepatorenal syndrome type 1 (HRS-1) in patients with cirrhosis and ascites is a functional, potentially reversible, form of acute kidney injury characterized by rapid (<2 wk) and progressive deterioration of renal function. Terlipressin is a synthetic vasopressin analogue that acts, via vascular vasopressin V1 receptors, as a systemic vasoconstrictor. We performed a phase 3 study to evaluate the efficacy and safety of intravenous terlipressin plus albumin vs placebo plus albumin in patients with HRS-1.

          Related collections

          Author and article information

          Journal
          Gastroenterology
          Gastroenterology
          Elsevier BV
          1528-0012
          0016-5085
          Jun 2016
          : 150
          : 7
          Affiliations
          [1 ] Department of Medicine, University of Arizona, Tucson, Arizona. Electronic address: tboyer@deptofmed.arizona.edu.
          [2 ] Department of Medicine, Virginia Commonwealth University, Richmond, Virginia.
          [3 ] Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
          [4 ] Department of Medicine, California Pacific Medical Center, San Francisco, California.
          [5 ] Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
          [6 ] Department of Medicine, Baylor University Medical Center, Dallas, Texas.
          [7 ] Department of Medicine, Northwestern University, Chicago, Illinois.
          [8 ] Ikaria Therapeutics, LLC, a Mallinckrodt Company, Hampton, New Jersey.
          [9 ] Orphan Therapeutics, Lebanon, New Jersey.
          Article
          S0016-5085(16)00217-1
          10.1053/j.gastro.2016.02.026
          26896734

          Comments

          Comment on this article